mk 0941
Small moleculeexperimental
Clinical trial activity
11 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2007 (NCT00511667)
Timeline
Indications
Studied for
Mechanism of action
- Hexokinase type IVACTIVATOR
GCK activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 3-((6-(ethylsulfonyl)-3-pyridinyl)oxy)-5-(2-hydroxy-1-methylethoxy)-n-(1-methyl-1h-pyrazol-3-yl)benzamide
- mk0941
- mk0941
- mk 0941
- mk-0941
- mk-0941
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01106287 | Phase 1 | Oct 1, 2009 | Merck |
| NCT00792935 | Phase 2 | Jan 1, 2009 | Merck |
| NCT00824616 | Phase 2 | Jan 1, 2009 | Merck |
| NCT00830791 | Phase 1 | Jan 1, 2009 | Merck |
| NCT00873821 | Phase 1 | Dec 1, 2008 | Merck |
| NCT00912002 | Phase 1 | Oct 1, 2008 | Merck |
| NCT00767000 | Phase 2 | Oct 1, 2008 | Merck |
| NCT00754130 | Phase 1 | Sep 1, 2008 | Merck |
| NCT00567112 | Phase 1 | Nov 1, 2007 | Merck |
| NCT00511472 | Phase 1 | Jul 1, 2007 | Merck |
| NCT00511667 | Phase 1 | May 1, 2007 | Merck |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 11 | 11 | 2 | 2007 |
1 organizations
Page 1 / 1